{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:36:41Z","timestamp":1783741001905,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01014-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:02:30Z","timestamp":1752141750000},"page":"768-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine\/tipiracil"],"prefix":"10.1007","volume":"14","author":[{"given":"Jun","family":"Takami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Nakakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7006-130X","authenticated-orcid":false,"given":"Ryosuke","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"10","key":"1014_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13(10):993\u20131001.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1014_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909\u201319.","journal-title":"N Engl J Med"},{"issue":"4","key":"1014_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36(4):350\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1014_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau H-T, Prokharau A, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437\u201348.","journal-title":"Lancet Oncol"},{"issue":"Spec Feature","key":"1014_CR5","first-page":"97","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA. Lonsurf (trifluridine plus tipiracil): a new oral treatment approved for patients with metastatic colorectal cancer. Am Health Drug Benefits. 2016;9(Spec Feature):97\u2013100.","journal-title":"Am Health Drug Benefits"},{"key":"1014_CR6","unstructured":"Les Laboratoires Servier. Lonsurf (trifluridine\/tipiracil) [package insert]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lonsurf-epar-product-information_en.pdf"},{"issue":"10","key":"1014_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1159\/000509375","volume":"144","author":"G Desbuissons","year":"2020","unstructured":"Desbuissons G, Ngango L, Broch\u00e9riou I, Fournier P. IgA nephropathy associated with trifluridine\/tipiracil: a case report. Nephron. 2020;144(10):506\u20138.","journal-title":"Nephron"},{"key":"1014_CR8","doi-asserted-by":"crossref","unstructured":"Aria AB, Chen L, Glass WF, Lahoti A, Chon SY. Leukocytoclastic vasculitis with late-onset Henoch-Sch\u00f6nlein purpura after trifluridine\/tipiracil treatment. Dermatol Online J. 2018;24(10). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30677817\/","DOI":"10.5070\/D32410041721"},{"issue":"5","key":"1014_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.kint.2020.05.053","volume":"98","author":"F Fakhouri","year":"2020","unstructured":"Fakhouri F, Le Quintrec M, Fr\u00e9meaux-Bacchi V. Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int. 2020;98(5):1135\u201348.","journal-title":"Kidney Int"},{"issue":"4","key":"1014_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","volume":"31","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011;31(4):341\u20138.","journal-title":"Semin Nephrol"},{"issue":"2","key":"1014_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.ackd.2022.02.009","volume":"29","author":"A Jeyabalan","year":"2022","unstructured":"Jeyabalan A, Trivedi M. Paraneoplastic glomerular diseases. Adv Chronic Kidney Dis. 2022;29(2):116-126.e1.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"1014_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3904\/kjim.2013.28.2.254","volume":"28","author":"J-H Ryu","year":"2013","unstructured":"Ryu J-H, Chung SS, Ryu D-R, Kim S-J, Kang D-H, Sung SH, et al. A case of membranoproliferative glomerulonephritis associated with metastatic colon cancer. Korean J Intern Med. 2013;28(2):254\u20137.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"1014_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13256-016-0979-3","volume":"10","author":"S Chan","year":"2016","unstructured":"Chan S, Oliver KA, Gray NA. An association between membranoproliferative glomerulonephritis and metastatic colorectal carcinoma: a case report. J Med Case Rep. 2016;10(1):199.","journal-title":"J Med Case Rep"},{"issue":"2","key":"1014_CR14","first-page":"31","volume":"45","author":"G Severova","year":"2024","unstructured":"Severova G, Karanfilovski V, Naunovska L, Suleyman S, Markovska ZS, Gjorgjievski N, et al. Association between membranoproliferative glomerulonephritis and colorectal cancer\u2014a case report. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024;45(2):31\u20136.","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"issue":"3","key":"1014_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2215\/CJN.06410613","volume":"9","author":"N Masani","year":"2014","unstructured":"Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014;9(3):600\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1014_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"THJ Goodship","year":"2017","unstructured":"Goodship THJ, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91(3):539\u201351.","journal-title":"Kidney Int"},{"issue":"1","key":"1014_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrneph.2010.152","volume":"7","author":"T Nakagawa","year":"2011","unstructured":"Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, Kosugi T, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7(1):36\u201344.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"1014_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684\u2013700.","journal-title":"Mod Pathol"},{"issue":"4","key":"1014_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ekir.2022.01.1048","volume":"7","author":"H Trujillo","year":"2022","unstructured":"Trujillo H, Sandino J, Cavero T, Caravaca-Font\u00e1n F, Guti\u00e9rrez E, Sevillano \u00c1M, et al. IgA nephropathy is the most common underlying disease in patients with anticoagulant-related nephropathy. Kidney Int Rep. 2022;7(4):831\u201340.","journal-title":"Kidney Int Rep"},{"key":"1014_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbrc.2022.04.063","volume":"610","author":"H-J Jia","year":"2022","unstructured":"Jia H-J, Zhou M, Vashisth MK, Xia J, Hua H, Dai Q-L, et al. Trifluridine induces HUVECs senescence by inhibiting mTOR-dependent autophagy. Biochem Biophys Res Commun. 2022;610:119\u201326.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1014_CR21","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.3390\/jcm9124050","volume":"9","author":"K Tsunekuni","year":"2020","unstructured":"Tsunekuni K, Kawakami H, Matsuoka K, Nagase H, Mitani S, Nakagawa K. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, FTD\/TPI, with ramucirumab Murine version DC101 in a mouse syngeneic cancer transplantation model. J Clin Med. 2020;9(12):4050.","journal-title":"J Clin Med"},{"key":"1014_CR22","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","volume":"13","author":"T Mazzierli","year":"2022","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharmacol. 2022;13:1088031.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1014_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187\u2013200.","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"1014_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93(24):333\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"24","key":"1014_CR25","volume":"30","author":"WSC Padilha","year":"2023","unstructured":"Padilha WSC, Cesar BN, Pacheco ST, De Sousa AA, Ledesma FL, Malheiros DMAC, et al. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case report. Am J Case Rep. 2023;30(24): e940906.","journal-title":"Am J Case Rep"},{"issue":"9","key":"1014_CR26","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","volume":"45","author":"J Usui","year":"2014","unstructured":"Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol. 2014;45(9):1918\u201327.","journal-title":"Hum Pathol"},{"issue":"2","key":"1014_CR27","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","volume":"49","author":"BA George","year":"2007","unstructured":"George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007;49(2):e23\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1014_CR28","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21(8):1381\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1014_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","volume":"20","author":"R Yamada","year":"2019","unstructured":"Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019;20(1):14.","journal-title":"BMC Nephrol"},{"issue":"3","key":"1014_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-239603","volume":"14","author":"Y Nakano","year":"2021","unstructured":"Nakano Y, Kumagai J, Nagahama K, Fujisawa H. A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings. BMJ Case Rep. 2021;14(3): e239603.","journal-title":"BMJ Case Rep"},{"issue":"8","key":"1014_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s10147-023-02357-3","volume":"28","author":"S Dote","year":"2023","unstructured":"Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, et al. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study. Int J Clin Oncol. 2023;28(8):1054\u201362.","journal-title":"Int J Clin Oncol"},{"issue":"18","key":"1014_CR32","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388(18):1657\u201367.","journal-title":"N Engl J Med"},{"key":"1014_CR33","unstructured":"Taiho Pharmaceutical Co. LONSURF (trifluridine and tipiracil) [package insert]. [cited 2024 Nov 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207981s012lbl.pdf"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01014-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:05:17Z","timestamp":1758719117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01014-0","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the World Medical Association\u2019s Declaration of Helsinki. The Ethics Committee of Ome Medical Center determined that ethical approval was not required for this single case report. Written informed consent was obtained for the publication of medical details. No personal identifying information is included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}